{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_004",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:52f9317256343704f06df5dcbb35be12935bb4e70dddf56f8423cd1dbf9724ca",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:00:00.074379",
  "content": "## 2024-03-25 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 80\n- Active: 80\n- Screen Failures Cumulative: 6\n- Withdrawals Cumulative: 0\n\n### Enrollment by Dose Group\n- Low Dose: 20\n- Mid Dose: 21\n- High Dose: 20\n- Placebo: 19\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 32.6\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 16.9\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 46.4\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC per 10e6) Mean: 85.0\n  - CD4 Response (SFC per 10e6) SD: 15.0\n  - CD8 Response (SFC per 10e6) Mean: 54.0\n  - CD8 Response (SFC per 10e6) SD: 11.0\n  - Seroconversion Percentage: 12.1\n- Mid Dose\n  - IgG Titer (GMU) Mean: 52.1\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 25.3\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 80.7\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC per 10e6) Mean: 120.0\n  - CD4 Response (SFC per 10e6) SD: 24.0\n  - CD8 Response (SFC per 10e6) Mean: 90.0\n  - CD8 Response (SFC per 10e6) SD: 18.0\n  - Seroconversion Percentage: 19.6\n- High Dose\n  - IgG Titer (GMU) Mean: 71.3\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 33.2\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 122.2\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC per 10e6) Mean: 178.0\n  - CD4 Response (SFC per 10e6) SD: 33.0\n  - CD8 Response (SFC per 10e6) Mean: 121.0\n  - CD8 Response (SFC per 10e6) SD: 24.0\n  - Seroconversion Percentage: 25.2\n- Placebo\n  - IgG Titer (GMU) Mean: 11.3\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 0.7\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 8.0\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC per 10e6) Mean: 25.0\n  - CD4 Response (SFC per 10e6) SD: 3.0\n  - CD8 Response (SFC per 10e6) Mean: 10.0\n  - CD8 Response (SFC per 10e6) SD: 2.0\n  - Seroconversion Percentage: 0.9\n\n### Injection Site Reactions\n- Pain Percentage: 53.7\n- Erythema Percentage: 12.6\n- Swelling Percentage: 17.6\n- Induration Percentage: 4.4\n- Mean Pain Duration (Hours): 18.8\n\n### Systemic Reactogenicity\n- Fever Percentage: 19.9\n- Fatigue Percentage: 38.1\n- Myalgia Percentage: 30.2\n- Headache Percentage: 27.5\n- Chills Percentage: 10.1\n\n### Safety Labs\n- WBC (K) Mean: 7.1\n- WBC (K) SD: 1.3\n- Lymphocyte Percentage Mean: 32.0\n- Lymphocyte Percentage SD: 5.2\n- Neutrophil Percentage Mean: 63.7\n- Neutrophil Percentage SD: 5.4\n- Platelets (K) Mean: 218\n- Platelets (K) SD: 41\n- CRP (mg/L) Mean: 7.7\n- CRP (mg/L) SD: 1.9\n- Hemoglobin (g/dL) Mean: 14.2\n- Hemoglobin (g/dL) SD: 1.2\n\n### Adverse Events\n- AE ID: VI-AE-0417, Description: lymphadenopathy, Grade: 2, Relatedness: related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0429, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0425, Description: malaise, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Vaccination day 1: 21 subjects received scheduled dose\n- Immunology core lab QC report received\n\n### Notes\n- Week 4: Immunogenicity assessments on schedule. 80 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 4,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}